Scientific Reports And Studies Behind Turboforte

We are an internationally approved and recognised medical device that is proud to show our certifications.

Registered by the Australian Governments Therapeutic Goods Association (TGA).

Turboforte meets the European Union's (EU) standards for health, safety, and environmental protection.


Using the latest in medical innovation, we’ve created an answer for clearer, healthier and stronger lungs – all in one small but powerful package.

26+ million


8.3% of Americans have asthma. Of these 26.5 million, 20.4 million are adults and 6.1 million are children. Patients with asthma reported 11 million visits to a doctor’s office and 1.7 million visits to hospital outpatient departments.

8.9+ million


Bronchitis is inflammation of the bronchi, the air pathways to the lungs. In 2016, more than 8.9 million Americans were diagnosed with chronic bronchitis and nearly 75 percent of these cases involved people over the age of 45.

29+ million


Chronic obstructive pulmonary disease is a group of group of progressive lung diseases. The most common are emphysema and chronic bronchitis. There’s no cure for COPD, but treatment can help ease symptoms, lower the chance of complications. and generally improve quality of life.

Clinical Trials

Turboforte Lung Physio and other similar flutter valve devices have participated in many clinical trials, and have also undertaken rigorous testing in many hospitals and universities world-wide. Below is a representation of a few of the completed studies.